The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESH MPN 2026 | Is there potential for the use of vaccines in MPN treatment?
In this video, Morten Orebo Holmström, MD, PhD, National Center for Cancer Immune Therapy, Herlev Hospital, Copenhagen, Denmark, discusses challenges with integrating vaccine strategies into myeloproliferative neoplasm (MPN) treatment. Dr Holmström highlights that for vaccines to be effective, tumor burden must be low and the immune response must be very strong, noting that using vaccines after transplant and in combination with other treatments may optimize outcomes. This interview took place at the ESH 11th Translational Research Conference on Myeloproliferative Neoplasms (ESH MPN 2026) in Estoril, Portugal.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
